These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34150608)

  • 1. Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer.
    Guan X; Li C; Li Y; Wang J; Yi Z; Liu B; Chen H; Xu J; Qian H; Xu B; Ma F
    Front Oncol; 2021; 11():602222. PubMed ID: 34150608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.
    Wang Y; Liu Y; Zhang Z; Lu B; Gao Y; Tong L; Hu M; Lin PP; Li B; Zhang T
    BMC Cancer; 2023 Jun; 23(1):578. PubMed ID: 37349714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the prognostic role and biological characteristics of circulating tumor cell-associated white blood cell clusters in non-small cell lung cancer.
    Li Z; Fan L; Wu Y; Niu Y; Zhang X; Wang B; Yao Y; Chen C; Qi N; Wang DD; Lin PP; Tang D; Gao W
    J Thorac Dis; 2022 May; 14(5):1544-1555. PubMed ID: 35693614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cell associated white blood cell cluster as a biomarker for metastasis and recurrence in hepatocellular carcinoma.
    Chen J; Luo Y; Xi X; Li H; Li S; Zheng L; Yang D; Cai Z
    Front Oncol; 2022; 12():931140. PubMed ID: 36465354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of circulating tumor cells associated with white blood cells in solid cancer: a systematic review and meta-analysis of 1471 patients with solid tumors.
    Ju M; Gao Z; Gu G; Huang H; Sun A; Zheng C; Li H; Zhang Y; Li K
    BMC Cancer; 2023 Dec; 23(1):1224. PubMed ID: 38087278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
    Davies CR; Guo T; Burke E; Stankiewicz E; Xu L; Mao X; Scandura G; Rajan P; Tipples K; Alifrangis C; Wimalasingham AG; Galazi M; Crusz S; Powles T; Grey A; Oliver T; Kudahetti S; Shaw G; Berney D; Shamash J; Lu YJ
    Front Oncol; 2022; 12():1060864. PubMed ID: 36727071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor-Cell-Associated White Blood Cell Clusters in Peripheral Blood Indicate Poor Prognosis in Patients With Hepatocellular Carcinoma.
    Luo Q; Wang C; Peng B; Pu X; Cai L; Liao H; Chen K; Zhang C; Cheng Y; Pan M
    Front Oncol; 2020; 10():1758. PubMed ID: 33224869
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
    Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
    Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR
    Shao B; Li H; Zhang J; Liu X; Song G; Jiang H; Yan Y; Wang H; Wang J; Di L
    Ann Transl Med; 2022 Aug; 10(16):901. PubMed ID: 36111005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.
    Magbanua MJM; Savenkov O; Asmus EJ; Ballman KV; Scott JH; Park JW; Dickler M; Partridge A; Carey LA; Winer EP; Rugo HS
    Clin Cancer Res; 2020 Sep; 26(18):4911-4920. PubMed ID: 32586939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
    Li Y; Peng Z; Zhang X; Gong J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.
    Bidard FC; Jacot W; Kiavue N; Dureau S; Kadi A; Brain E; Bachelot T; Bourgeois H; Gonçalves A; Ladoire S; Naman H; Dalenc F; Gligorov J; Espié M; Emile G; Ferrero JM; Loirat D; Frank S; Cabel L; Diéras V; Cayrefourcq L; Simondi C; Berger F; Alix-Panabières C; Pierga JY
    JAMA Oncol; 2021 Jan; 7(1):34-41. PubMed ID: 33151266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
    Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
    Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.